JP2018518527A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518527A5
JP2018518527A5 JP2017567429A JP2017567429A JP2018518527A5 JP 2018518527 A5 JP2018518527 A5 JP 2018518527A5 JP 2017567429 A JP2017567429 A JP 2017567429A JP 2017567429 A JP2017567429 A JP 2017567429A JP 2018518527 A5 JP2018518527 A5 JP 2018518527A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
allogeneic
cell population
human patient
cmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017567429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518527A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/038530 external-priority patent/WO2016209816A1/en
Publication of JP2018518527A publication Critical patent/JP2018518527A/ja
Publication of JP2018518527A5 publication Critical patent/JP2018518527A5/ja
Pending legal-status Critical Current

Links

JP2017567429A 2015-06-26 2016-06-21 T細胞療法によるcmv網膜炎の治療方法 Pending JP2018518527A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562185558P 2015-06-26 2015-06-26
US62/185,558 2015-06-26
US201562191304P 2015-07-10 2015-07-10
US62/191,304 2015-07-10
PCT/US2016/038530 WO2016209816A1 (en) 2015-06-26 2016-06-21 Methods of treating cmv retinitis by t cell therapy

Publications (2)

Publication Number Publication Date
JP2018518527A JP2018518527A (ja) 2018-07-12
JP2018518527A5 true JP2018518527A5 (https=) 2019-08-08

Family

ID=56404300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567429A Pending JP2018518527A (ja) 2015-06-26 2016-06-21 T細胞療法によるcmv網膜炎の治療方法

Country Status (6)

Country Link
US (2) US10342864B2 (https=)
EP (2) EP3756676B1 (https=)
JP (1) JP2018518527A (https=)
CN (1) CN107921065A (https=)
HK (1) HK1254397A1 (https=)
WO (1) WO2016209816A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
US20210000874A1 (en) 2018-03-14 2021-01-07 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
EP3978554A4 (en) * 2019-05-28 2023-06-21 Toyobo Co., Ltd. POLYESTER FILM, LAMINATED FILM AND USE THEREOF
MX2022001322A (es) * 2019-07-29 2022-05-24 Baylor College Medicine Bancos de células t específicas de antígeno y métodos para fabricar y usar los mismos terapéuticamente.
RU2740943C1 (ru) * 2020-03-23 2021-01-21 Борис Сергеевич Першин Способ лечения цитомегаловирусного ретинита после трансплантации гемопоэтических стволовых клеток

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595978A (en) * 1990-08-16 1997-01-21 Isis Pharmaceuticals, Inc. Composition and method for treatment of CMV retinites
CN1237909A (zh) * 1996-10-11 1999-12-08 加利福尼亚大学董事会 联合使用肿瘤细胞与混合淋巴细胞的癌症免疫治疗
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6156317A (en) 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
ATE497971T1 (de) 1999-06-04 2011-02-15 Florian Kern Peptide zur vakzinierung gegen das humane cmv
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
AU2002214624A1 (en) 2000-10-20 2002-05-06 City Of Hope Immunoreactive peptide ctl epitopes of human cytomegalovirus pp150
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
AU2002351177A1 (en) * 2001-11-29 2003-06-10 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
WO2003073097A2 (en) 2002-02-28 2003-09-04 Intercell Ag Methods for isolating ligands e.g. t cell epitopes
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
CA2728739C (en) 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
CA2744449C (en) 2008-11-28 2019-01-29 Emory University Methods for the treatment of infections and tumors
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB0917094D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
WO2013063436A1 (en) * 2011-10-26 2013-05-02 Chimerix, Inc. Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
GB201121308D0 (en) * 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2017003763A1 (en) * 2015-06-27 2017-01-05 Memorial Sloan Kettering Cancer Center Methods of treating glioblastoma multiforme by t cell therapy

Similar Documents

Publication Publication Date Title
JP2018518527A5 (https=)
Zheng et al. Hepatitis B functional cure and immune response
Saez-Cirion et al. Immunometabolism and HIV-1 pathogenesis: food for thought
Archin et al. Eradicating HIV-1 infection: seeking to clear a persistent pathogen
Hel et al. HIV infection: first battle decides the war
Liu et al. HIV-1 functional cure: will the dream come true?
Luo et al. B cell response to vaccination
Chen et al. CRISPR-Cas targeting of host genes as an antiviral strategy
Brahmania et al. New therapeutic agents for chronic hepatitis B
Wong et al. Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak
Ng et al. IL-10: achieving balance during persistent viral infection
JP2017515901A5 (https=)
US20180177866A1 (en) Hiv pre-immunization and immunotherapy
Kamphorst et al. Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity
Ahluwalia et al. Infection and immune memory: variables in robust protection by vaccines against SARS-CoV-2
JP2018520095A5 (https=)
Ravens et al. Human γδ T cell receptor repertoires in peripheral blood remain stable despite clearance of persistent hepatitis C virus infection by direct-acting antiviral drug therapy
JP2014512391A5 (https=)
Wu et al. A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis
JP2012532624A5 (https=)
Hemann et al. Plasmacytoid dendritic cells require direct infection to sustain the pulmonary influenza A virus-specific CD8 T cell response
Martin et al. Influence of time and number of antigen encounters on memory CD8 T cell development
Conway et al. Cellular therapies for the treatment and prevention of SARS-CoV-2 infection
Ikeogu et al. Identifying physiological tissue niches that support the HIV reservoir in T cells
Kotton et al. Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023